A recent survey commissioned by the OSUCCC—James found that, while most U.S. adults identify family history (DNA-based risk passed down through families) as a risk factor for colorectal cancer, other factors such as alcohol use, lack of physical activity, and an American diet that is high in fat and processed foods were less known.
FDA announced its final decision to withdraw approval of Pepaxto (melphalan flufenamide), which was approved for use in combination with dexamethasone to treat certain patients with multiple myeloma.
FDA said grease-proofing materials containing per- and polyfluoroalkyl substances (PFAS) are no longer being sold for use in food packaging in the U.S.
FDA has granted Breakthrough Therapy Designation to Epkinly (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
FDA has accepted a Biologics License Application for Tevimbra (tislelizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Lixte Biotechnology has signed an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke and NCI.
Exact Sciences Corp. has launched the Riskguard hereditary cancer test in the United States.
The National Cancer Institute approved the following clinical research studies last month.
In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.
Feb. 16, 2024, is a landmark date in the history of immuno-oncology.
